Sage Journals: Discover world-class research

Abstract

Background:

FDA expedited program designations (EPDs) are intended to facilitate drug development for serious conditions with an unmet medical need. There are over 10 FDA-approved therapies for the rare disease pulmonary arterial hypertension (PAH). This work investigates the landscape of EPDs in the context of FDA-approved PAH therapies in order to inform on future drug development.

Methods:

The publicly available FDA Action Package (AP) was manually culled for information related to EPDs for 10 FDA-approved treatments for PAH. Documentation supporting the EPD request and/or its review (including potential rejection) was not found during the data cull.

Results:

This investigation finds that (1) only ambrisentan received the Fast Track Designation; (2) no Breakthrough Designations were elucidated; (3) bosentan and treprostinil received Accelerated Approval Designations, and (4) ambrisentan, sildenafil, riociguat, epoprostenol, iloprost, and treprostinil received Priority Review Designations. All therapies (except sildenafil) received an Orphan Drug Designation.

Conclusion:

Based on these results, it is recommended that drug developers be encouraged to revisit traditional endpoint measures, explore novel biological mechanisms, and/or effectively differentiate in other dimensions (eg, safety). Developers should also consider engaging the FDA early in development (ideally prior to first-in-human) to agree on the kind and amount of data to meet the statutory bar with the intention of increasing the probability of securing a Fast Track or Breakthrough Designation.

Keywords

FDA expedited program designations pulmonary arterial hypertension Fast Track Designation Breakthrough Therapy Designation Priority Review Designation Accelerated Approval Designation

Get full access to this article

View all access options for this article.

References

McLaughlin

Shah

Souza

Humbert

. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65:1976–1997.

Henriques-Forsythe

Annangi

Farber

. Prevalence and hospital discharge status of human immunodeficiency virus–associated pulmonary arterial hypertension in the United States. Pulm Circ. 2015;5:506–512.

Stein

Matta

Hughes

. Scope of problem of pulmonary arterial hypertension. Am J Med. 2015;128:844–851.

Hemnes

. Pulmonary Arterial Hypotension overview located on the National Organization for Rare Disorders (NORD). https://rarediseases.org/rare-diseases/pulmonary-arterial-hypertension/. Published 2015.

Souza

Jardim

Humbert

. Epidemiology and disease classification of pulmonary hypertension. In: Klinger

Frantz

, eds. Diagnosis and Management of Pulmonary Hypertension. Vol. 12. New York, NY: Humana Press; 2015:21–25.

FDA. The voice of the patient: pulmonary arterial hypertension. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM429382.pdf. Accessed January 5, 2016.

Boucherat

Vitry

Trinh

Provencher

Bonnet

. The cancer theory of pulmonary arterial hypertension. Pulm Circ. 2017;7:285–299.

DiMasi

Grabowski

Hansen

. The cost of drug development. N Engl J Med. 2015;372:1972.

Prasad

Mailankody

. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–1575.

10.

FDA. Interim rule, investigational new drug, antibiotic, and biological drug product regulations; procedures for drugs intended to treat life-threatening and severely debilitating illnesses. 53 FR 41516, October 21, 1988.

11.

FDA. Guidance for Industry: expedited programs for serious conditions—drugs and biologics. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Published May 2014.

12.

Guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension. Doc. Ref. EMEA/CHMP/EWP/356954/2008.

13.

Hwang

Darrow

Kesselheim

. The FDA’s expedited programs and clinical development times for novel therapeutics 2012-2016. J Am Med Assoc. 2017;318:2137–2138.

14.

Galiè

Humbert

Vachiery

. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.

15.

Daizadeh

. Analyzing United States prescribing information to gain insight into FDA-sponsor discussions. J Commercial Biotech. 2011;17:218–229.

16.

Fleming

. Surrogate endpoints and FDA’s accelerated approval process. Health Aff. 2005;24:67–78.

17.

Kesselheim

Darrow

. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes. Clin Pharm Ther. 2014;97:29–36.

18.

Sun

Stockbridge

Ariagno

Murphy

. Pharmacology review: the role of biomarkers and surrogate end point in drug development of neonatal pulmonary arterial hypertension. NeoReviews. 2016;17:e87–e92.

19.

Cottin

Price

Valenzuela

. The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. Eur Respir J. 2018;51:1702596.

20.

Nathan

Behr

Cottin

. Idiopathic interstitial pneumonia-associated pulmonary hypertension: a target for therapy? Respir Med. 2017;122:S10–S13.

21.

Divers

Platt

Wang

Lin

Lingohr-Smith

Mathai

. A review of clinical trial endpoints of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and how they relate to patient outcomes in the United States. J Manag Care Spec Pharm. 2016;23:92–104.

22.

FDA Guidance. Common issues in drug development: guidance for industry. 2015.

23.

Chary

. Expedited drug review process: fast, but flawed. J Pharmacol Pharmacother. 2016;7:57–61.

24.

Daniel

Richardson

Streit

. Breakthrough therapy designation: a primer. Brookings Institute. https://www.brookings.edu/blog/health360/2015/04/21/breakthrough-therapy-designation-a-primer/. Published 2015.

25.

McLauglin

Gains

Barst

; Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293–299.

26.

FDA Action Package – Remodulin Administration (Part 2). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin_admindocs_P2.pdf.

27.

LeVarge

Channick

. The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints. Curr Opin Pulm Med. 2015;21:438–445.

28.

Statement FDA: Patient Engagement (2017) Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm579842.htm. Published October 11, 2017.

29.

FDA Statement: Targeted Therapies (2017) Statement from FDA Commissioner Scott Gottlieb, M.D., on new FDA efforts to support more efficient development of targeted therapies. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589248.htm. Published December 15, 2017.

30.

FDA Statement: Digital Health (2017) Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing new digital health policies to encourage innovation, bring efficiency and modernization to regulation. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587890.htm. Published December 7, 2017.

31.

Approval of an NDA and an ANDA. Title 21: Food and Drugs. Applications for FDA Approval to Market a New Drug. 21 CFR §314.105.

Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations

Abstract

Background:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References